Classes
DEA Class; Rx
Common Brand Names; Alfenta, Rapifen
- Synthetic, Opioids;
- Opioids, Anilidopiperidine
Description
Alfentanil is a synthetic opiate agonist primarily used in anesthesia, especially in settings where hemodynamic stability is critical (e.g., cardiovascular surgery). Fentanyl is 5-8 times more potent than alfentanil, but alfentanil has a faster onset and shorter duration of action.
Indications
Indicated for use during general anesthesia induction and general anesthesia maintenance.
Contraindications
Hypersensitivity
Increased intracranial pressure
Severe respiratory depresssion
Adverse Effects
Arrhythmia (14%)
Bradycardia (14%)
Chest wall rigidity (17%)
Hypertension (18%)
Nausea (28%)
Vomiting (18%)
Tachycardia (12%)
Apnea (3-9%)
Blurred vision (1-3%)
Dizziness (3-9%)
Hypotension (10%)
Post-op respiratory depression (1-3%)
Skeletal muscle movements (3-9%)
Postoperative sedation (1-3%)
Sweating, flushing
Warmness of the face/neck/upper thorax
Pruritus
urticaria
Respiratory (undefined)
Respiratory/circulatory depression
Respiratory arrest
Shock
Cardiac arrest
Nervous System (undefined)
Dizziness
Visual disturbances
Mental clouding/depression
Sedation
Coma
Euphoria
Dysphoria
Weakness
Faintness
Agitation
Restlessness
Nervousness
Seizures
GI (undefined)
Nausea
Vomiting
Constipation
Cardiovascular (undefined)
QT-interval prolongation
Severe cardiac arrhythmias
Cardiac arrest
ST segment elevation
VTach
MI
Angina pectoris
Syncope
Genitourinary (undefined)
Urinary retention
Oliguria
Cholinergic (undefined)
Bradycardia
Dry mouth
Palpitation
Tachycardia
Warnings
Use caution in bradycardia, compromised cardiac reserve, head injury, hypothyroidism, increased ICP, intracranial lesions, renal impairment, respiratory impairment, obesicty, history of drug abuse
Concurrent administration of benzodiazepine or neuromuscular blocker will decrease chest wall rigidity
Should be administered by trained individuals
In patients who may be susceptible to intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), therapy may reduce respiratory drive, and resultant CO2 retention can further increase intracranial pressure; monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy; opioids may obscure clinical course in a patient with a head injury; avoid the use in patients with impaired consciousness or coma
May cause spasm of sphincter of Oddi; opioids may cause increases in serum amylase; monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms
Therapy may increase frequency of seizures in patients with seizure disorders and in other clinical settings associated with seizures; monitor patients for worsened seizure control during therapy
Pregnancy and Lactation
Prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome; available data in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage
Lactation: use with caution
Maximum Dosage
The maximum dosage is dependent on indication for therapy.
The maximum dosage is dependent on indication for therapy.
The maximum dosage is dependent on indication for therapy.
Safe and effective use has not been established.
How supplied
Alfentanil hydrochloride
injectable solution: Schedule II
- 0.5mg/mL
Dose should be calculated based on ideal body weight